TY - JOUR
T1 - Self-rated measure of pain frequency, intensity, and burden
T2 - Psychometric properties of a new instrument for the assessment of pain
AU - dela Cruz, Adriane M.
AU - Bernstein, Ira H.
AU - Greer, Tracy L.
AU - Walker, Robrina
AU - Rethorst, Chad D.
AU - Grannemann, Bruce
AU - Carmody, Thomas
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Madhukar H. Trivedi is or has been an advisor/consultant to: Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Inc. , Cyberonics, Inc. , National Alliance for Research in Schizophrenia and Depression , National Institute of Mental Health ( U01MH092221 , T32MH0675-43 , HHSN2712011000061 , HHSNiHMH2010-24 ), National Institute on Drug Abuse ( 5U01DA020024 ), Novartis , Pharmacia & Upjohn , Predix Pharmaceuticals (Epix) , and Solvay Pharmaceuticals, Inc. Tracy Greer has received research funding from NARSAD and is a paid consultant for H. Lundbeck A/S . Ira Bernstein has received grant support from the Joint Research Committee of the National Council Of State Boards Of Nursing and serves on the advisory board of the Joint Research Committee of the National Council of State Boards of Nursing. He receives book royalties from Sage Publications and owns stock in the following companies: Merck & Co Inc, Bristol-Myers Squibb Company, DuPont, EI. de Nemours & CC. All other authors declare they have no conflicts of interest.
Funding Information:
Research reported in this publication was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U10DA020024 (PI: MH Trivedi). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No division of NIH had any further role in study design; in data collection, analysis, or interpretation; in the preparation of the manuscript; or in the decision to submit the manuscript for publication.
Publisher Copyright:
© 2014 Elsevier Ltd. All rights reserved.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background: A brief, self-administered measurement of pain frequency, intensity, and burden is desirable in both research and clinical settings. We describe the development and initial psychometric properties of a new instrument, the Pain Frequency, Intensity, and Burden Scale (P-FIBS). Methods: The P-FIBS was administered to all participants (N=302) with psychostimulant use disorders in the National Institute on Drug Abuse Clinical Trials Network's STRIDE (Stimulant Reduction Intervention using Dose Exercise) multisite trial. Results: The four items on the P-FIBS demonstrate high item-total correlations (range 0.70-0.85) with a high Cronbach's alpha (0.90). The P-FIBS demonstrated a strong negative correlation with the bodily pain sub-score of the Short Form Health Survey (r=-0.76, p<0.0001) and did not correlate with a measure of cocaine (r=0.09, p=0.12) or methamphetamine (r=-0.06, p=0.33) craving. Conclusions: The P-FIBS demonstrates good psychometric properties. This brief measure can be used to assess pain in research settings or as a screen in clinical settings. Further research is needed to assess the measure's sensitivity to change with treatment.
AB - Background: A brief, self-administered measurement of pain frequency, intensity, and burden is desirable in both research and clinical settings. We describe the development and initial psychometric properties of a new instrument, the Pain Frequency, Intensity, and Burden Scale (P-FIBS). Methods: The P-FIBS was administered to all participants (N=302) with psychostimulant use disorders in the National Institute on Drug Abuse Clinical Trials Network's STRIDE (Stimulant Reduction Intervention using Dose Exercise) multisite trial. Results: The four items on the P-FIBS demonstrate high item-total correlations (range 0.70-0.85) with a high Cronbach's alpha (0.90). The P-FIBS demonstrated a strong negative correlation with the bodily pain sub-score of the Short Form Health Survey (r=-0.76, p<0.0001) and did not correlate with a measure of cocaine (r=0.09, p=0.12) or methamphetamine (r=-0.06, p=0.33) craving. Conclusions: The P-FIBS demonstrates good psychometric properties. This brief measure can be used to assess pain in research settings or as a screen in clinical settings. Further research is needed to assess the measure's sensitivity to change with treatment.
KW - Assessment
KW - Pain
KW - Psychometrics
KW - Rating scale
UR - http://www.scopus.com/inward/record.url?scp=84908340308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908340308&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2014.08.003
DO - 10.1016/j.jpsychires.2014.08.003
M3 - Article
C2 - 25194231
AN - SCOPUS:84908340308
SN - 0022-3956
VL - 59
SP - 155
EP - 160
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
ER -